Adlai Nortye

Adlai Nortye

Adlai Nortye

Adlai Nortye engages in research and development of biopharmaceuticals for cancer immunotherapy.
Founded
2004
Raised
$100M
Follow us
Latest funding
$100,000,000
Venture capital (Series C) - 2020
Yingke PE Hangzhou Tigermed Consulting ATCG Holdings +1
Team Size
1–10
Employees
Location
Headquarters
$100,000,000 Venture capital (Series C)
ChinaMoneyNetwork

Chinese Biopharma Firm Adlai Nortye Raises $100M In Series C Round – China Money Network

FinSMEs

Adlai Nortye Biopharma Raises $53M in Series B Financing

Funding Health